Shanghai-based FOSUN PHARMA has released its 2025 Environmental, Social and Governance (ESG) & Sustainability Report, outlining advances in green operations, global health access and governance standards. The report covers the period 1 Jan – 31 Dec 2025 and has been assured by SGS-CSTC.
Double-Digit ESG Ratings and Governance Upgrades • MSCI ESG rating lifted to “AA”, with Hang Seng Indexes maintaining an “A-” grade. • Fortune China listed FOSUN PHARMA as the only domestic pharmaceutical company in its 2025 ESG Impact List. • ESG indicators now weigh at least 10 % in senior management appraisals.
Innovation and Product Accessibility • R&D expenditure reached RMB 5.91 billion, equivalent to 14.19 % of annual revenue. • Seven innovative drugs/biosimilars with 16 indications were approved, including Fu Mai Ning and Fu Tuo Ning for rare tumours. • Five orphan-drug indications are now approved; nearly 10 additional rare-disease indications are under development. • Henlius products have obtained approvals in 60 countries and regions, benefiting over 1 million patients worldwide. • Ejilunsai (Yi Kai Da) CAR-T therapy is covered by more than 110 Chinese city insurance plans; 210 hospitals are certified for treatment.
Climate and Environmental Metrics • Capital investment in environmental protection approached RMB 80 million. • Photovoltaic generation hit 31.37 million kWh; an additional 45.70 million kWh of green power was procured, avoiding 24,248 tons CO₂e. • Comprehensive energy-consumption intensity fell 6.8 % year-on-year to 1.717 GJ per RMB 10,000 revenue. • Carbon-emission intensity dropped to 0.203 ton CO₂e per RMB 10,000 revenue, meeting the 2025 target ahead of schedule. • Water-saving projects reduced consumption by 391,000 m³, 4 % of total usage.
Supply-Chain Responsibility • 1,031 supplier quality audits were completed; 30 key suppliers underwent green-supply-chain assessments, all rated three-star or above. • The company joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member.
Occupational Health and Safety • No work-related fatalities; lost-time-injury rate improved to 0.092 per million working hours. • RMB 678.81 million was allocated to safety and fire-protection facilities and operations.
Community Impact • Over the past three years, cumulative charitable donations exceeded RMB 400 million. • Rural Doctor Programme now covers 78 counties, supporting 25,000 rural doctors and benefiting three million rural households. • In 2025 the company donated 900,000 courses of WHO-certified antimalarial drugs to Angola, Tanzania and Kenya.
Workforce Development • Total headcount stood at 40,603, with women representing 51.19 %. • Average training hours reached 51 per employee; 100 % of staff received anti-corruption training. • Young Partner and “Star YAO” programmes enhanced talent pipelines; turnover declined to 11.92 %.
Outlook The Board reiterates its commitment to the strategic pillars of “Innovation-Driven, Deep Globalisation and AI Embracement”, pledging to deepen green practices, expand global medicine accessibility and uphold rigorous governance as it advances toward its 2030 sustainability targets.